Cardiomegaly

• 

  Subject Areas on Research

  • A Simple Score That Predicts Paroxysmal Atrial Fibrillation on Outpatient Cardiac Monitoring after Embolic Stroke of Unknown Source. 
  • A new (heat) shocking player in cardiac hypertrophy. 
  • A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. 
  • A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. 
  • A role for the thromboxane receptor in L-NAME hypertension. 
  • A six-month-old boy with neonatal lupus and cardiac enlargement. 
  • A systems genetics approach identifies Trp53inp2 as a link between cardiomyocyte glucose utilization and hypertrophic response. 
  • ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. 
  • Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. 
  • Ablation of Sirtuin5 in the postnatal mouse heart results in protein succinylation and normal survival in response to chronic pressure overload. 
  • Accumulation and endocrine disrupting effects of the flame retardant mixture Firemaster® 550 in rats: an exploratory assessment. 
  • Adaptive mechanisms that preserve cardiac function in mice without myoglobin. 
  • Akt/protein kinase B promotes organ growth in transgenic mice. 
  • Alterations in diastolic function in response to progressive left ventricular hypertrophy. 
  • Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease. 
  • An improved technique for producing ventricular hypertrophy with a subcoronary valvular aortic stenosis model. 
  • Angiotensin II Type 1A Receptor Expressed in Smooth Muscle Cells is Required for Hypertensive Vascular Remodeling in Mice Infused With Angiotensin II. 
  • Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. 
  • Angiotensin II type 1 receptor-associated protein is an endogenous inhibitor of angiotensin II type 1 receptor action in cardiac hypertrophy: role in check and balance. 
  • Angiotensin converting enzyme inhibitors and the cardiovascular system. 
  • Apolipoprotein J/clusterin induction in myocarditis: A localized response gene to myocardial injury. 
  • Autocrine and paracrine mechanisms in the pathophysiology of heart failure. 
  • Basic diagnostic echocardiography. 
  • Bbeta-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by beta- but not alpha1-adrenergic stimulation. 
  • Beta-adrenergic axis and heart disease. 
  • Beta-adrenergic control of c-fos expression in fetal and neonatal rat tissues: relationship to cell differentiation and teratogenesis. 
  • Beta-adrenergic receptor desensitization in cardiac hypertrophy and heart failure. 
  • Beyond fitness tracking: The use of consumer-grade wearable data from normal volunteers in cardiovascular and lipidomics research. 
  • Calcineurin signaling in human cardiac hypertrophy. 
  • Calcium signaling regulates ventricular hypertrophy during development independent of contraction or blood flow. 
  • Calcium-dependent gene regulation in myocyte hypertrophy and remodeling. 
  • Cantú syndrome: report of nine new cases and expansion of the clinical phenotype. 
  • Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. 
  • Cardiac hypertrophy and altered beta-adrenergic signaling in transgenic mice that express the amino terminus of beta-ARK1. 
  • Cardiac hypertrophy and sudden death in mice with a genetically clamped renin transgene. 
  • Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. 
  • Cardiac hypertrophy: role of G protein-coupled receptors. 
  • Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. 
  • Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload. 
  • Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort. 
  • Cardiac sarcoidosis: two cases with autopsy findings. 
  • Cardiac transplantation in a pediatric patient with systemic sclerosis. 
  • Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3β and TGF-β1-Smad signalling. 
  • Challenges of comparative expression profiling studies of complex diseases: mouse models of myocardial hypertrophy. Focus on "Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy". 
  • Characteristics of chronic left ventricular hypertrophy induced by subcoronary valvular aortic stenosis. I. Myocardial blood flow and metabolism. 
  • Characteristics of chronic left ventricular hypertrophy induced by subcoronary valvular aortic stenosis. II. Response to ischemia. 
  • Chest pain in the nontraumatized patient. 
  • Chronic N(G)-nitro-L-arginine methyl ester-induced hypertension : novel molecular adaptation to systolic load in absence of hypertrophy. 
  • Chronic elevation of calmodulin in the ventricles of transgenic mice increases the autonomous activity of calmodulin-dependent protein kinase II, which regulates atrial natriuretic factor gene expression. 
  • Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. 
  • Clinical applications of echocardiography in myocardial and valvular heart disease. 
  • Clinical implications of isopotential surface maps. 
  • Clinical problem-solving. A key miscommunication--an 81-year-old woman presented to the emergency department with increasing abdominal distention, nausea, and vomiting. 
  • Clinical problem-solving. Undercover and overlooked. 
  • Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. 
  • Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice. 
  • Contribution of afterload, hypertrophy and geometry to left ventricular ejection fraction in aortic valve stenosis, pure aortic regurgitation and idiopathic dilated cardiomyopathy. 
  • Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. 
  • Creatinine kinase kinetics studied by phosphorus-31 nuclear magnetic resonance in a canine model of chronic hypertension-induced cardiac hypertrophy. 
  • DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. 
  • Dawn of the Epi-LncRNAs: new path from Myheart. 
  • Decreased beta-adrenergic responsiveness following hypertrophy occurs only in cardiomyocytes that also re-express beta-myosin heavy chain. 
  • Deletion of MLIP (muscle-enriched A-type lamin-interacting protein) leads to cardiac hyperactivation of Akt/mammalian target of rapamycin (mTOR) and impaired cardiac adaptation. 
  • Depressed high-energy phosphate content in hypertrophied ventricles of animal and man: the biologic basis for increased sensitivity to ischemic injury. 
  • Development of the linkage of beta-adrenergic receptors to cardiac hypertrophy and heart rate control: neonatal sympathectomy with 6-hydroxydopamine. 
  • Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. 
  • Direct Actions of AT1 (Type 1 Angiotensin) Receptors in Cardiomyocytes Do Not Contribute to Cardiac Hypertrophy. 
  • Discordant on/off switching of gene expression in myocytes during cardiac hypertrophy in vivo. 
  • Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. 
  • Disruption of mindin exacerbates cardiac hypertrophy and fibrosis. 
  • Disruption of sarcoendoplasmic reticulum calcium ATPase function in Drosophila leads to cardiac dysfunction. 
  • Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. 
  • Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. 
  • Divergent pathways mediate the induction of ANF transgenes in neonatal and hypertrophic ventricular myocardium. 
  • Does hypertension potentiate atherosclerosis via vascular hypertrophy? 
  • Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. 
  • Early adaptive chromatin remodeling events precede pathologic phenotypes and are reinforced in the failing heart. 
  • Effect of a dominant negative ras on myocardial hypertrophy by using adenoviral-mediated gene transfer. 
  • Effects of growth hormone and IGF-I on cardiac hypertrophy and gene expression in mice. 
  • Elastic properties of normal and hypertrophied cardiac muscle. 
  • Electrocardiographic and hemodynamic correlations in patients with idiopathic hypertrophic subaortic stenosis. 
  • Electrocardiographic diagnosis of exercise-induced left ventricular hypertrophy. 
  • Elucidating the molecular mechanism of cardiac remodeling using a comparative genomic approach. 
  • Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. 
  • Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. 
  • Epicardial activation and repolarization patterns in patients with right ventricular hypertrophy. 
  • Epigenomic regulation of heart failure: integrating histone marks, long noncoding RNAs, and chromatin architecture. 
  • Estimation of wall stress and left ventricular mass by noninvasive techniques and clinical implications. 
  • Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy. 
  • Etiology and differential diagnosis of acute mitral regurgitation. 
  • Evaluation of vectorcardiographic criteria for the diagnosis of myocardial infarction in the presence of left ventricular hypertrophy. 
  • Evolution of the clinical management of hypertension. Emerging role of "specific" vasodilators as initial therapy. 
  • Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. 
  • FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes. 
  • Fill a Gab(1) in cardiac hypertrophy signaling: search a missing link between gp130 and ERK5 in hypertrophic remodeling in heart. 
  • G protein-coupled receptor signalling in in vivo cardiac overload. 
  • GATA4 and the two sides of gene expression reprogramming. 
  • Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. 
  • Gene therapy: role in myocardial protection. 
  • Genesis of body surface potentials in varying types of right ventricular hypertrophy. 
  • Genetic Abrogation of Adenosine A3 Receptor Prevents Uninephrectomy and High Salt-Induced Hypertension. 
  • Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. 
  • Gi-biased β2AR signaling links GRK2 upregulation to heart failure. 
  • Heart hypertrophy during pregnancy: a better functioning heart? 
  • Heart size-independent analysis of myocardial function in murine pressure overload hypertrophy. 
  • High-Resolution Mapping of Chromatin Conformation in Cardiac Myocytes Reveals Structural Remodeling of the Epigenome in Heart Failure. 
  • Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. 
  • Hypertension and cardiovascular hypertrophy during chronic catecholamine infusion in rats. 
  • Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. 
  • Hypertrophy, fibrosis and diastolic dysfunction in early canine experimental hypertension. 
  • Images in clinical medicine. Malignant pericardial effusion. 
  • Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. 
  • Improved tolerance to ischemia in hypertrophied myocardium by preischemic enhancement of adenosine triphosphate. 
  • In hypertension, the kidney breaks your heart. 
  • Independent association of cognitive dysfunction with cardiac hypertrophy irrespective of 24-h or sleep blood pressure in older hypertensives. 
  • Inducible Fgf13 ablation enhances caveolae-mediated cardioprotection during cardiac pressure overload. 
  • Induction of immediate-early genes by angiotensin II and endothelin-1 in adult rat cardiomyocytes. 
  • Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. 
  • Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. 
  • Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. 
  • Interferon regulatory factors in heart: stress response beyond inflammation. 
  • Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. 
  • Ischemic cardiomyopathy: the myopathy of coronary artery disease. Natural history and results of medical versus surgical treatment. 
  • Isopotential surface maps. 
  • JNK1 is required to preserve cardiac function in the early response to pressure overload. 
  • Junctophilin-2 expression silencing causes cardiocyte hypertrophy and abnormal intracellular calcium-handling. 
  • Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. 
  • Left atrial enlargement: a cause of stroke? 
  • Left ventricular function is not impaired in weight-lifters who use anabolic steroids. 
  • Limited value of interlaced ECG-gated radiography in the presence of a normal chest radiograph. 
  • Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. 
  • Loss of Bmx nonreceptor tyrosine kinase prevents pressure overload-induced cardiac hypertrophy. 
  • Loss of Endothelial Hypoxia Inducible Factor-Prolyl Hydroxylase 2 Induces Cardiac Hypertrophy and Fibrosis. 
  • Lymphocyte responses exacerbate angiotensin II-dependent hypertension. 
  • MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. 
  • Mapping genetic contributions to cardiac pathology induced by Beta-adrenergic stimulation in mice. 
  • Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. 
  • Metabolomics-assisted proteomics identifies succinylation and SIRT5 as important regulators of cardiac function. 
  • Methods for the detection of altered beta-adrenergic receptor signaling pathways in hypertrophied hearts. 
  • Molecular and functional signature of heart hypertrophy during pregnancy. 
  • Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophy. 
  • Myocardial Lipin 1 knockout in mice approximates cardiac effects of human LPIN1 mutations. 
  • Myocardial Na+/H+ exchanger-1 (NHE1) content is decreased by exercise training. 
  • Myocardial blood flow and oxygen consumption in the empty-beating, fibrillating, and potassium-arrested hypertrophied canine heart. 
  • Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. 
  • Myocardial hypertrophy in the ischemic zone induced by exercise in rats after coronary reperfusion. 
  • Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. 
  • Myocardin induces cardiomyocyte hypertrophy. 
  • Neonatal methylmercury poisoning in the rat: effects on development of peripheral sympathetic nervous system. Neuronal participation in methylmercury-induced cardiac and renal overgrowth. 
  • Network integration of the adrenergic system in cardiac hypertrophy. 
  • Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function. 
  • Nrg1 is an injury-induced cardiomyocyte mitogen for the endogenous heart regeneration program in zebrafish. 
  • Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. 
  • Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. 
  • Phosphate: a novel cardiovascular risk factor. 
  • Physiological induction of a beta-adrenergic receptor kinase inhibitor transgene preserves ss-adrenergic responsiveness in pressure-overload cardiac hypertrophy. 
  • Positive Role for a Negative Calcineurin Regulator in Cardiac Hypertrophy. 
  • Post-translational regulation of calsarcin-1 during pressure overload-induced cardiac hypertrophy. 
  • Predictive capability of left atrial size measured by CT, TEE, and TTE for recurrence of atrial fibrillation following radiofrequency catheter ablation. 
  • Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. 
  • Pressure overload selectively up-regulates Ca2+/calmodulin-dependent protein kinase II in vivo. 
  • Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. 
  • Pressure-overload hypertrophy is unabated in mice devoid of AT1A receptors. 
  • Quantitative analysis of the chromatin proteome in disease reveals remodeling principles and identifies high mobility group protein B2 as a regulator of hypertrophic growth. 
  • RBFox1-mediated RNA splicing regulates cardiac hypertrophy and heart failure. 
  • RIP140 deficiency enhances cardiac fuel metabolism and protects mice from heart failure. 
  • Rapid ventricular filling in left ventricular hypertrophy: I. Physiologic hypertrophy. 
  • Regulation of myocardial betaARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing alpha1B-adrenergic receptors. 
  • Relationship of disease-associated gene expression to cardiac phenotype is buffered by genetic diversity and chromatin regulation. 
  • Relative wall thickness analysis by two-dimensional echocardiography. 
  • Remodeling and reparation of the cardiovascular system. 
  • Remodeling muscles with calcineurin. 
  • Response of hypertrophied myocardium to ischemia: correlation with biochemical and physiological parameters. 
  • Restriction of big hearts by a small RNA. 
  • Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. 
  • Right ventricular isolation procedures for nonischemic ventricular tachycardia. 
  • Roentgenographic abnormalities in Rocky Mountain Spotted Fever. 
  • Role for thromboxane receptors in angiotensin-II-induced hypertension. 
  • Role of AT₁ receptor-mediated salt retention in angiotensin II-dependent hypertension. 
  • Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. 
  • Role of ornithine decarboxylase in cardiac growth and hypertrophy. 
  • Role of phosphoinositide 3-kinase in cardiac function and heart failure. 
  • Role of polyamines in isoproterenol-induced cardiac hypertrophy: effects of alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase. 
  • Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. 
  • Sensing heart stress. 
  • Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. 
  • Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. 
  • Signal transduction in cardiac hypertrophy--dissecting compensatory versus pathological pathways utilizing a transgenic approach. 
  • Sirtuin 5 is required for mouse survival in response to cardiac pressure overload. 
  • Smad3 Signaling Promotes Fibrosis While Preserving Cardiac and Aortic Geometry in Obese Diabetic Mice. 
  • Socioeconomic status and morbidity and mortality in hypertensive blacks. 
  • Socking It to cardiac hypertrophy: STIM1-mediated Ca2+ entry in the cardiomyocyte. 
  • Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease. 
  • Sperm DNA methylation alterations from cannabis extract exposure are evident in offspring. 
  • Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. 
  • Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. 
  • Systems Genetics Approach Identifies Gene Pathways and Adamts2 as Drivers of Isoproterenol-Induced Cardiac Hypertrophy and Cardiomyopathy in Mice. 
  • Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes. 
  • TASK-1 and TASK-3 channels modulate pressure overload-induced cardiac remodeling and dysfunction. 
  • TRPC1 channels are critical for hypertrophic signaling in the heart. 
  • Targeted expression of calmodulin increases ventricular cardiomyocyte proliferation and deoxyribonucleic acid synthesis during mouse development. 
  • The chromatin-binding protein Smyd1 restricts adult mammalian heart growth. 
  • The elusive philosopher's stone in young blood. 
  • The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. 
  • The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure. 
  • The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure. 
  • The preexcitation syndromes. 
  • The relationship between 'job strain,' workplace diastolic blood pressure, and left ventricular mass index. Results of a case-control study. 
  • The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. 
  • The structural proteins of normal and diseased human myocardium. 
  • The two-pore domain potassium channel TREK-1 mediates cardiac fibrosis and diastolic dysfunction. 
  • Tissue renin-angiotensin system in myocardial hypertrophy and failure. 
  • Transverse shape characteristics of cardiac myocytes from rats and humans. 
  • UNUSUAL NEUROLOGICAL AND CARDIOVASCULAR COMPLICATIONS OF RESPIRATORY FAILURE. 
  • Vasopressin: a new target for the treatment of heart failure. 
  • Vegfaa instructs cardiac muscle hyperplasia in adult zebrafish. 
  • Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. 
  • What the dead can teach the living: systemic nature of heart failure with preserved ejection fraction. 
  • [Giant left atrium combined with mitral valvular disease: morphologic classification and its clinical significance]. 
  • p38 MAP kinases in the heart. 
  • p53 functions in endothelial cells to prevent radiation-induced myocardial injury in mice. 
• 

  Keywords of People

  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology